Cargando…
Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57)
INTRODUCTION: There are limited real-world data on the prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes mellitus (T2DM). METHODS: This was a retrospective analysis of the CoDiC® database of the Japan Diabetes Clinical Data Management Study Group...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843848/ https://www.ncbi.nlm.nih.gov/pubmed/33300091 http://dx.doi.org/10.1007/s13300-020-00977-w |
_version_ | 1783644215888052224 |
---|---|
author | Ishigaki, Yasushi Strizek, Alena Aranishi, Toshihiko Arai, Nobuhiro Imaoka, Takeshi Cai, Zhihong Maegawa, Hiroshi |
author_facet | Ishigaki, Yasushi Strizek, Alena Aranishi, Toshihiko Arai, Nobuhiro Imaoka, Takeshi Cai, Zhihong Maegawa, Hiroshi |
author_sort | Ishigaki, Yasushi |
collection | PubMed |
description | INTRODUCTION: There are limited real-world data on the prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes mellitus (T2DM). METHODS: This was a retrospective analysis of the CoDiC® database of the Japan Diabetes Clinical Data Management Study Group (JDDM). Demographic and clinical characteristics, concomitant treatment patterns, and GLP-1 RA treatment persistence or modification in patients with T2DM initiating GLP-1 RA therapy were evaluated. RESULTS: The analysis included 932 eligible patients with T2DM who had their first GLP-1 RA prescription (index date) between September 2016 and July 2018. Mean age was 63.8 years and 56.0% were male. Most patients had an index GLP-1 RA of dulaglutide (65.7%) or liraglutide (29.1%). Common comorbidities were obesity (58.7%), hypertension (54.7%), dyslipidemia (52.0%), retinopathy (11.3%), and nephropathy (10.2%). Mean hemoglobin A1c (HbA1c) levels decreased from 8.3 to 7.8% over 6 months after GLP-1 RA initiation, and the proportion of patients achieving HbA1c < 7.0% increased from 14.4% at index date to 22.9% at 6 months. Reductions occurred in mean body weight, body mass index, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and adjusted urinary albumin over 6 months. Antidiabetic medication use decreased after GLP-1 RA initiation, whereas non-antidiabetic medication prescribing showed little change. Index GLP-1 RA persistence rates were 80.5%, 66.2%, and 51.6% at 6, 12, and 18 months post-index, respectively, with a median persistence until discontinuation or switch of 600 days. Persistence rates at 6, 12, and 18 months post-index, respectively, were 81.9%, 70.7%, and 65.4% for dulaglutide and 79.7%, 60.0%, and 30.4% for liraglutide. CONCLUSION: The study shows real-world benefits of GLP-1 RA therapy for T2DM, including improvements in HbA1c, body weight, and blood lipid profile, and supports the high rates of long-term persistence previously reported with dulaglutide, the GLP-1 RA most commonly prescribed for T2DM in Japanese clinical practice. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s13300-020-00977-w) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7843848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-78438482021-02-04 Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) Ishigaki, Yasushi Strizek, Alena Aranishi, Toshihiko Arai, Nobuhiro Imaoka, Takeshi Cai, Zhihong Maegawa, Hiroshi Diabetes Ther Original Research INTRODUCTION: There are limited real-world data on the prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes mellitus (T2DM). METHODS: This was a retrospective analysis of the CoDiC® database of the Japan Diabetes Clinical Data Management Study Group (JDDM). Demographic and clinical characteristics, concomitant treatment patterns, and GLP-1 RA treatment persistence or modification in patients with T2DM initiating GLP-1 RA therapy were evaluated. RESULTS: The analysis included 932 eligible patients with T2DM who had their first GLP-1 RA prescription (index date) between September 2016 and July 2018. Mean age was 63.8 years and 56.0% were male. Most patients had an index GLP-1 RA of dulaglutide (65.7%) or liraglutide (29.1%). Common comorbidities were obesity (58.7%), hypertension (54.7%), dyslipidemia (52.0%), retinopathy (11.3%), and nephropathy (10.2%). Mean hemoglobin A1c (HbA1c) levels decreased from 8.3 to 7.8% over 6 months after GLP-1 RA initiation, and the proportion of patients achieving HbA1c < 7.0% increased from 14.4% at index date to 22.9% at 6 months. Reductions occurred in mean body weight, body mass index, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and adjusted urinary albumin over 6 months. Antidiabetic medication use decreased after GLP-1 RA initiation, whereas non-antidiabetic medication prescribing showed little change. Index GLP-1 RA persistence rates were 80.5%, 66.2%, and 51.6% at 6, 12, and 18 months post-index, respectively, with a median persistence until discontinuation or switch of 600 days. Persistence rates at 6, 12, and 18 months post-index, respectively, were 81.9%, 70.7%, and 65.4% for dulaglutide and 79.7%, 60.0%, and 30.4% for liraglutide. CONCLUSION: The study shows real-world benefits of GLP-1 RA therapy for T2DM, including improvements in HbA1c, body weight, and blood lipid profile, and supports the high rates of long-term persistence previously reported with dulaglutide, the GLP-1 RA most commonly prescribed for T2DM in Japanese clinical practice. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s13300-020-00977-w) contains supplementary material, which is available to authorized users. Springer Healthcare 2020-12-09 2021-01 /pmc/articles/PMC7843848/ /pubmed/33300091 http://dx.doi.org/10.1007/s13300-020-00977-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Ishigaki, Yasushi Strizek, Alena Aranishi, Toshihiko Arai, Nobuhiro Imaoka, Takeshi Cai, Zhihong Maegawa, Hiroshi Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) |
title | Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) |
title_full | Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) |
title_fullStr | Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) |
title_full_unstemmed | Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) |
title_short | Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57) |
title_sort | glucagon-like peptide-1 receptor agonist utilization in type 2 diabetes in japan: a retrospective database analysis (jddm 57) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843848/ https://www.ncbi.nlm.nih.gov/pubmed/33300091 http://dx.doi.org/10.1007/s13300-020-00977-w |
work_keys_str_mv | AT ishigakiyasushi glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 AT strizekalena glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 AT aranishitoshihiko glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 AT arainobuhiro glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 AT imaokatakeshi glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 AT caizhihong glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 AT maegawahiroshi glucagonlikepeptide1receptoragonistutilizationintype2diabetesinjapanaretrospectivedatabaseanalysisjddm57 |